Publications by authors named "Daniel Serin"

Claim this Profile
P
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Elie Rassy, Thomas Filleron, Alessandro Viansone, Magali Lacroix-Triki, Sofia Rivera, Daniel Serin

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Study to Assess a Systematic Screening of Occupational Exposures in Lung Cancer Patients.
Olivia Pérol, Nadège Lepage, Hugo Noelle, Pierre Lebailly, Benoit de Labrusse, Daniel Serin

Int J Environ Res Public Health· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Cancers induced by occupational exposure: What progress has been made?].
Benoit Delabrusse, Brigitte Le Meur, Léa Vazquez, Rania Boustany, Daniel Serin

Bull Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
Véronique D'Hondt, Jean-Luc Canon, Lise Roca, Christelle Levy, Jean-Yves Pierga, Daniel Serin

Eur J Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Daniel Serin

Lancet· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Supportive care for survivors].
Grégory Ninot, Philippe Debourdeau, Françoise Blanc-Legier, Françoise De Crozals, Gaétan De Rauglaudre, Daniel Serin

Bull Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, Christelle Levy, Alain Lortholary, Daniel Serin

Eur J Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives.
Jennifer Cautela, Nathalie Lalevée, Chloé Ammar, Stéphane Ederhy, Michael Peyrol, Daniel Serin

Int J Cardiol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up of Patients Treated for pT1aN0M0 Breast Cancer: 10-year Survival and Prognostic Factors.
Patrice Crochet, Nicolas Molinari, Jean-Claude Darmon, Bruno Cutuli, Daniel Serin

Breast J· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
["SOS SEIN 84" accelerated breast disease management: Patients satisfaction survey].
Antoine Arnaud, Magali Dumuids, Alice Mège, Gaëtan de Rauglaudre, Anne Regis Arnaud, Daniel Serin

Bull Cancer· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Methods of development of recommendations for clinical practice (RCP) and of setting-up of a platform cancer heart vessels (PTF-CHV) in the inter3C Vaucluse-Arles].
Philippe Debourdeau, Catherine Meuleman, Ghislaine Dufaitre, Jean-Pierre Laroche, Borhane Slama, Daniel Serin

Bull Cancer· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].
Jean-Yves Pierga, Rémy Delva, Xavier Pivot, Marc Espié, Florence Dalenc, Daniel Serin

Bull Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
Sandrine Baffert, Paul Cottu, Youlia M Kirova, Florence Mercier, Cécile Simondi, Daniel Serin

BMC Health Serv Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Daniel Serin

Lancet Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Bruno Coudert, Bernard Asselain, Mario Campone, Marc Spielmann, Jean-Pascal Machiels, Daniel Serin

Oncologist· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Physical activity and cancer survival].
Isabelle Romieu, Marina Touillaud, Pietro Ferrari, Yves-Jean Bignon, Sami Antoun, Daniel Serin

Bull Cancer· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, Benjamin Esterni, Daniel Serin

Breast Cancer Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Anne-Claire Hardy-Bessard, Rémy Delva, Xavier Pivot, Marc Espié, Florence Dalenc, Daniel Serin

Bull Cancer· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and feasibility of a set of quality indicators relative to the timeliness and organisation of care for new breast cancer patients undergoing surgery.
Marie Ferrua, Mélanie Couralet, Gérard Nitenberg, Sandrine Morin, Daniel Serin

BMC Health Serv Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.
Elisabeth Luporsi, Fabrice André, Frédérique Spyratos, Pierre-Marie Martin, Jocelyne Jacquemier, Daniel Serin

Breast Cancer Res Treat· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Jean-Marc Extra, Eric C Antoine, Anne Vincent-Salomon, Thierry Delozier, Pierre Kerbrat, Daniel Serin

Oncologist· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Marc Spielmann, Henri Roché, Thierry Delozier, Jean-Luc Canon, Gilles Romieu, Daniel Serin

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer screening in France: subjects' and physicians' attitudes.
François Eisinger, Jean-Yves Blay, Jean-François Morère, Olivier Rixe, Anne Calazel-Benque, Daniel Serin

Cancer Causes Control· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of organised programs on colorectal cancer screening.
François Eisinger, Laurent Cals, Anne Calazel-Benque, Jean-Yves Blay, Yvan Coscas, Daniel Serin

BMC Cancer· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.
Claire Julian-Reynier, Jean Genève, Florence Dalenc, Dominique Genre, Alain Monnier, Daniel Serin

J Clin Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis